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ELECTRONIC LETTER
Little value from including cousins in individual risk
assessment of hereditary breast cancer: a simulation
study
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Breast cancer is a common disease in women. The lifetimerisk of breast cancer is about 1 in 12 in the UK, 1 in 10 inThe Netherlands, and 1 in 8 in the USA.1 The majority of
women are affected in the peri- or postmenopausal years:
about 75% of all breast cancer cases are diagnosed after the
age of 50.2 In western countries about 5 to 10% of breast can-
cer is the result of a genetic predisposition. The most
important genes that are involved in this genetic predisposi-
tion and have been localised are BRCA1 and BRCA2,3 4 but these
genes only explain a small proportion of the aggregation of
breast cancer.5 The lifetime risk of breast and ovarian cancer in
BRCA1 and BRCA2 mutation carriers is high, and women are
generally affected at younger ages. The recent detection of
these cancer genes has led to much media attention. As a con-
sequence, an increasing number of women with one or more
relatives with breast cancer visits a family cancer clinic with
questions about their risk of developing breast cancer. At these
clinics the woman’s risk of breast cancer based on the family
history can be assessed. The aim of this risk assessment is to
identify women with a genetic susceptibility and an associated
increased risk of developing breast cancer. The individual risk
assessment is very important, particularly for the women
whose risk of developing breast cancer is deemed to be at least
moderately increased, because decisions have to be made
about breast surveillance and possibly DNA testing. This leads
to an increasing need for accurate prediction methods to
assess individual risks of breast cancer.
Current guidelines for risk assessment are often based on
the family history of breast cancer in the first and second
degree relatives.6 In the presence of a dominant mutation, and
especially in the case of a dominant disorder with complete
penetrance at birth, it may be possible to detect the lineage in
a pedigree along which a mutation was inherited. The more
extended a pedigree is, the easier it is to detect these lineages.
Consequently, it can be hypothesised that using additional
information on third degree relatives improves the accuracy of
risk assessment and may lead to a therapeutic strategy that is
more appropriate for the counsellee. However, collecting and
incorporating this information may be very time consuming,
especially if all pathology reports must be considered. Only if
for a sufficient number of counsellees the additional
information leads to a more appropriate therapeutic strategy
is it worth changing the current guidelines in order to base
medical decisions on third degree relatives too. This was
evaluated for the counsellees’ female cousins by means of a
simulation study. This study and the results found are
described in this paper. Other third degree relatives were not
considered, since these relatives are in general either too
young to have been affected by breast cancer or they had died
a long time ago, which makes information less reliable.
METHODS
Pedigree structure
In real life all pedigrees are different and it is impossible to
consider all possible pedigrees separately. Therefore the simu-
lations were based on one (common) pedigree, which is
shown in fig 1. The age is shown for each family member; it is
either the current age or the age at death. The choice of the
pedigree was mainly based on the counsellees and their fami-
lies who consult our family cancer clinic.7 Counsellees are
often aged between 30 and 45 years. In the main analysis, the
age of the counsellee in the pedigree was therefore taken as
equal to 35 years of age. In the sensitivity analysis, a pedigree
with a counsellee of 45 years of age was also considered. The
counsellee has one sister and eight female cousins. Children of
the counsellee in the pedigree are not taken into account,
because they would be too young to have developed breast
cancer (even if the counsellee is 45 years of age). Male cousins
have been excluded from the pedigree, because males are
rarely affected by breast cancer at a young age.
Key points
• In family cancer clinics a person’s risk of breast cancer
is assessed based on the family history of breast and
ovarian cancer. These risks are computed in order to
decide whether the subject will be offered further diag-
nosis. Therefore, risk assessment needs to be accurately
performed. Risk assessment is often based on the family
history of breast and ovarian cancer of first and second
degree relatives. In this paper, we studied whether
information on cousins improves the accuracy of risk
assessment.
• A simulation study was performed. For a chosen
pedigree, the genotype and phenotype of all family
members were simulated 10 million times. For this
simulation, the model presented in Claus et al
(1991) was used. A selection criterion was used in
order to select the pedigrees of which a particular
female in the pedigree, the counsellee, visited a family
cancer clinic. For each selected pedigree, risk
assessment for the counsellee was performed based on
her family history of breast cancer including and
excluding information on the cousins. The computed
risks were evaluated.
• In about 2% of the selected pedigrees, inclusion of
information on the cousins led to a different therapeutic
strategy for the counsellee. The results are not very sen-
sitive to the pedigree that is chosen and the genetic
model that is used.
• Information on the breast cancer history of cousins
seldom improves the accuracy of risk assessment and,
thus, the additional effort of seeking and incorporating





For the simulation study the genetic model presented in Claus
et al8 was used. In this model, the familial clustering of breast
cancer is explained by a dominant mode of inheritance that is
represented by one theoretical gene. The mutant allele on this
theoretical gene is supposed to be autosomal dominant and
the mutant allele frequency was taken as equal to 0.0033. The
penetrance function for female carriers is 0.928 times a
normal distribution with a mean of 55.435 and a standard
deviation of 15.387. For female non-carriers, this curve is
0.100 times a normal distribution with a mean of 68.990 and
a standard deviation of 15.387.
Simulation
The genotype and phenotype of all family members in the
pedigree were simulated in two steps. First, the alleles of the
single gene for the founders in the pedigree were simulated.
The alleles that were simulated were either normal or
mutated. The remaining subjects in the pedigree were given
alleles by inheriting them from their parents. The alleles,
either mutated or not, were inherited independently. Second,
given the genotype of a female, her phenotype was simulated
whether she would develop breast cancer, and if so at what
age. The whole simulation procedure was repeated 10 million
times. So, in total, a set with 10 million pedigrees was
simulated; each pedigree had its own genotypic and pheno-
typic combination among the family members in the pedigree.
Outcomes
The vast majority of women who visit a clinical genetic centre
have questions on the genetic nature of the cancer in their
family and on their breast cancer risk7 (when a woman visits
a family cancer clinic for information concerning her daugh-
ter’s breast cancer risk, this daughter is seen as the counsellee
and not the female who visits the clinic). Females who are
genetically susceptible to breast cancer are often recognised by
the young age (below the age of 50) at which they or family
members were affected by breast cancer. The analysis in the
simulation study was, therefore, focused on those women who
were free of breast cancer and who met the following
criterion: the women had at least one first degree relative with
breast cancer before the age of 50 or at least two second degree
relatives with breast cancer before the age of 50, in the pater-
nal or the maternal family or in both. For all pedigrees that
met the inclusion criterion, the counsellee’s risk of carrying a
mutation and developing breast cancer before the age of 75
was computed twice. The first time the computations were
based on the family history of breast cancer up to the second
degree relatives. The second time, third degree relatives (the
female cousins) were also incorporated into the computations.
These computations were carried out in a similar way to Par-
migiani et al.9 In these computations, the mutant allele
frequency and the penetrance functions given in Claus et al8
were used again. So, the risk assessment yields two outcomes:
the counsellee’s risk of developing breast cancer before the age
of 75 based on her family history up to second and up to third
Figure 1 The pedigree used in the simulation study. The age is shown for each family member; it is either the current age or the age at death.
The arrow is pointing to the counsellee, the woman whose risk of breast cancer was assessed.
Table 1 Counsellees offered further diagnostics when
information on cousins was included or excluded from
the risk assessment. Number of pedigrees that met one













15% Exclusive 55 171 (30.1) 13 585 (24.6)
Inclusive 55 276 (30.2) 13 692 (24.8)
20% Exclusive 34 983 (19.1) 10 788 (30.8)
Inclusive 34 357 (18.7) 10 847 (31.6)
30% Exclusive 15 118 (8.25) 6377 (42.2)
Inclusive 15 776 (8.61) 6709 (42.5)
40% Exclusive 6435 (3.51) 3052 (47.4)
Inclusive 7185 (3.92) 3384 (47.1)
Table 2 Sensitivity and specificity of the two
diagnostic tests (for different values of the threshold)





excluding cousins Sensitivity (%) Specificity (%)
15% Exclusive 75.9 74.9
Inclusive 76.5 74.9
20% Exclusive 60.3 85.4
Inclusive 60.6 85.8
30% Exclusive 36.6 94.7
Inclusive 37.5 94.5
40% Exclusive 17.1 98.0
Inclusive 18.9 97.7
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degree relatives. Since the data were simulated, the mutation
status of the counsellee was also known.
Analysis
Counsellees with a cumulative risk of breast cancer above a
certain threshold are, in general, referred for further
diagnosis. In the analysis, the thresholds 15%, 20%, 30%, and
40% were considered. A threshold of 15% corresponds with a
slightly increased risk of breast cancer. The thresholds 20%
and 30% are often used to distinguish between low, moderate,
and high risk families10 and a threshold of 40% corresponds
with a considerably increased risk. For each threshold, two
tables were made. In the first table, the counsellees were clas-
sified as to their mutation status and whether they were
offered further diagnosis based on their family history of
breast cancer up to second degree relatives (diagnostic test up
to degree 2). In the second table, the counsellees were classi-
fied in a similar way, but the decision about further diagnosis
was additionally based on information on the counsellee’s
female cousins (diagnostic test up to degree 3). The simulated
mutation status was taken as a gold standard and for each
threshold the sensitivity and specificity were calculated for the
two diagnostic tests. Moreover, receiver operator characteristic
(ROC) curves were constructed for when the female cousins
were included and excluded in the risk assessment (the ROC
curve is a plot of the sensitivity versus 1-specificity of a diag-
nostic test for all possible thresholds for referring a
counsellee). Furthermore, the areas under the curves were
calculated.
Sensitivity analyses
To check whether the structure of the pedigree used substan-
tially influenced the results, the analysis was also performed
for two pedigrees with a different structure: a small and a
large pedigree. These pedigrees were obtained by adjusting the
pedigree in fig 1. The small pedigree was obtained by remov-
ing the uncle and an aunt from the paternal side and two
aunts from the maternal side (including their spouses and
their children). The large pedigree was obtained by adding an
uncle and an aunt (with spouses) each with two daughters on
the paternal side and two uncles (with spouses) also with two
daughters each on the maternal side. All cousins included
were 38 years of age. In order to check whether the age of the
counsellee and her family members influenced the results, the
simulation study was also performed for the pedigree in fig 1
with all ages increased by 10 years. For each of the three pedi-
grees, the simulation procedure was performed 5 million
times and the sensitivity and specificity of the diagnostic tests
were computed based on the pedigrees that satisfied the
inclusion criterion.
RESULTS
Of the 10 million simulated pedigrees, 183 286 pedigrees
(1.8%) met the selection criterion. In 9.8% of these selected
pedigrees, the counsellee carried a mutation. In table 1 it can
be seen that the percentages of counsellees referred for further
diagnosis and the percentages of mutation carriers among
these referred counsellees are merely dependent upon the
threshold that is used for referring. Whether or not
information on cousins is included in the risk assessment only
marginally influences the results. Slightly more mutation car-
riers would be offered further diagnosis if information on
cousins was included. The percentage of pedigrees for which
the decision regarding further diagnosis differed in the two
situations was very small, between 1% and 2% depending on
the threshold used.
Results regarding the sensitivity and specificity of the two
diagnostic tests for different values of the threshold are given
in table 2. It appears that the changes in sensitivity and
specificity are also merely dependent upon the threshold that
is used for referring instead of the inclusion and exclusion of
information on cousins. The higher the threshold, the lower
the sensitivity (that is, the more mutation carriers are missed)
and the higher the specificity (that is, the less non-mutation
carriers are offered further diagnostic assessment). Fig 2
shows the ROC curves for both diagnostic tests. The curves
overlap almost completely. The areas under the two curves
equalled 0.80 and 0.81 for the tests where cousins were
excluded and included, respectively.
The simulation study was performed for three more
pedigrees. For each pedigree the number of counsellees that
were referred and the number of mutation carriers among
these referred counsellees are presented in table 3. The sensi-
tivity and specificity of the two diagnostic tests for different
Figure 2 ROC curves of the two diagnostic tests.
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values of the threshold are given in table 4. Again, the
percentage of referred counsellees, the percentage of mutation
carriers, as well as the sensitivity and specificity merely
depend on the structure of the pedigree, the ages of the fam-
ily members, and the threshold, but hardly on the inclusion or
exclusion of the breast cancer history of the cousins. So, the
choice of the structure of the pedigree and the ages of the
family members in the pedigree did not substantially
influence the results.
DISCUSSION
The decision to proceed with further diagnosis seldom
depended on the choice of inclusion or exclusion of
information on female cousins in the risk assessment. The
sensitivity and specificity of the two diagnostic tests for
further assessment based on information on the counsellee’s
family history of breast cancer including and excluding the
counsellee’s female cousins slightly differed for each thresh-
old. So, most information is obtained from the first and second
degree relatives. The choice of the pedigree structure and the
ages of the family members did not substantially affect these
results.
The counsellee’s cousins are of the same generation as the
counsellee and they are therefore also between about 30 and
45 years of age. At their young age they are seldom affected by
breast cancer. Only if one or more cousins are affected by
breast (or ovarian) cancer and the first and second degree
relatives do not give sufficient evidence for the presence of a
mutation may the information on the cousins be valuable in
risk assessment. This may, for instance, be the case if the
counsellee does not have paternal aunts and one or more of
her paternal cousins are affected by breast cancer. Such situa-
tions are rare. The effort necessary to ask the counsellee about
the cancer history of her cousins is minimal. Therefore, an
option is to collect information on the cancer history of the
cousins by asking the counsellee. Based on the information
obtained, it can be decided whether it may be useful to
consider pathology reports and to incorporate cousins in risk
assessment. The results in this paper showed that this proce-
dure seldom leads to more appropriate advice for the counsel-
lee.
The criterion for including pedigrees in the simulation
study probably had no affect on the results. Easing or tighten-
ing the criteria would merely affect the number of counsellees
who would not be offered further assessment, no matter
whether cousins are included in the risk assessment or not.
The inclusion criteria only concern first and second degree
relatives. Females with a clustering of breast cancer among the
cousins instead of breast cancer in the first and second degree
Table 3 Counsellees offered further diagnostics when information on cousins was
excluded and included from the risk assessment. The numbers of pedigrees that met













Small pedigree 81 749 (1.6%) 20% Exclusive 12 304 (15.1) 3607 (29.3)
Inclusive 12 396 (15.2) 3667 (29.6)
30% Exclusive 4982 (6.1) 1914 (38.4)
Inclusive 5084 (6.2) 1975 (38.8)
Large pedigree 97 074 (1.9%) 20% Exclusive 19 997 (20.6) 5977 (29.9)
Inclusive 20 138 (20.7) 6177 (30.7)
30% Exclusive 7701 (7.9) 3230 (41.9)
Inclusive 8551 (8.8) 3630 (42.5)
Age + 10 124 912 (2.5%) 20% Exclusive 16 804 (13.5) 5233 (31.1)
Inclusive 17 501 (14.0) 5545 (31.7)
30% Exclusive 9535 (7.6) 3624 (38.0)
Inclusive 10 293 (8.2) 3979 (38.7)
Table 4 Sensitivity and specificity of the two diagnostic tests for different pedigrees
and for different values of the threshold. The numbers of selected pedigrees that the




excluding cousins Sensitivity (%) Specificity (%)
Small pedigree (81 749) 20% Exclusive 47.7 88.3
Inclusive 48.5 88.2
30% Exclusive 25.3 95.9
Inclusive 26.1 95.8
Large pedigree (97 074) 20% Exclusive 60.5 83.9
Inclusive 62.6 84.0
30% Exclusive 32.7 94.9
Inclusive 36.8 94.4
Age + 10 (124 912) 20% Exclusive 57.4 90.0
Inclusive 60.8 89.7
30% Exclusive 39.7 94.9
Inclusive 43.6 94.5
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relatives may also visit a family cancer clinic for help. However,
these situations are rarely encountered in our family cancer
clinic and they were therefore not considered.
In the simulation study, the model presented in Claus et al8
was used. In this model, the familial clustering of breast can-
cer is explained by only one hypothetical gene. Ovarian cancer,
bilateral breast cancer, and breast cancer among males are not
included in the model. Because the BRCA1 and BRCA2 genes
are not only involved in genetic breast cancer susceptibility,
but also in hereditary ovarian cancer, bilateral breast cancer,
and breast cancer among males, it would be of interest to use
a genetic model that is based on this information as well. The
analysis described in this paper was also carried out for a
genetic model with the BRCA1 and BRCA2 genes. The mutant
allele frequencies for BRCA1 and BRCA2 as well as the
penetrance functions for mutation carriers were taken as used
by Parmigiani et al.9 Ovarian cancer, bilateral breast cancer,
and male breast cancer were also modelled as described in the
same paper.9 Similar conclusions to those described above
were found (results not shown). Again, only if one or more
cousins have had breast or ovarian cancer and the family
members in the first and second degree do not give sufficient
evidence for the presence of a mutation may the information
on the cousins be important in risk assessment. Such
situations are rare. The BRCA1 and BRCA2 genes only partly
explain the family clustering of breast cancer.5 A genetic
model with only these genes systematically underestimates
the risk of breast cancer in many pedigrees and is therefore
not applicable for risk assessment in family cancer clinics.
In some subpopulations, the mutant allele frequency is
considerably higher than in the general population. In order to
find out whether the results still hold for these subpopula-
tions, the simulation study as described in this paper was per-
formed for a mutant allele frequency 10 times the mutant
allele frequency in the model used before8; the new mutant
allele frequency equals 0.033. By this change the sensitivities
and specificities of the diagnostic tests increase and decrease,
respectively. However, the values of these quantities still
hardly depend on whether information on the breast cancer
history of cousins was included or not. Also, the medical
treatment that is offered would be altered if cousins were
included in the risk assessment for just a small percentage of
the counsellees.
The thresholds that are often used in guidelines for further
management of counsellees are 20% and 30%.10 A cumulative
risk of developing breast cancer of at least 30% is often taken
as a threshold for further genetic assessment. This genetic
assessment may include DNA testing. A cumulative risk
between 20% and 30% is often taken as a threshold for
surveillance, like breast self-examination, palpation, and
mammography once a year. A cumulative risk under 20% is
often used to imply that special interventions will not be cost
effective. Therefore, based on the results of the present study
it can be concluded that the accuracy of the risk assessment
just slightly decreases if information on cousins is not taken
into account. For a threshold of 20%, the additional
information on the cousins led to a different therapeutic
strategy in about 1% of the counsellees. This percentage
increased to 2% if a threshold of 30% was used. Only some of
these cases involve misclassification if information on the
cousins is not used in the risk assessment (a pedigree is
wrongly classified if either the counsellee carries a mutation
and is not referred for further diagnosis or she does not carry
a mutation, but is referred). These wrongly classified pedigrees
are difficult to characterise; no difference in the phenotype of
the family members in pedigrees of counsellees with and
without a mutation was found. Similar results hold if other
thresholds are used in guidelines to distinguish between low,
moderate, and high risk families.11
The results in this paper show that in general the additional
effort of systematically collecting and incorporating infor-
mation on the breast cancer history of cousins in family can-
cer clinics is not rewarding. Only in rare situations does the
inclusion of the breast cancer history of cousins in the decision
making lead to more appropriate advice for the counsellee.
The information on the breast cancer history of cousins is
often not very accurate. This even further weakens the
argument for seeking and basing medical decisions on the
information found. We conclude that cousins do not have to be
incorporated in the guidelines for risk assessment.
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